Gastrointestinal and liver disease-focused Metacrine has filed to go public having raised $125m from investors including Eli Lilly.

The Capital One and Salesforce-backed data management platform developer - valued at $12.4bn in February - has filed to go public.

The Dell-backed software management technology provider was valued at $1.5bn as of October and has initially filed to raise $100m.

Baxter Ventures is set to exit the kidney dialysis device maker, which has just filed to go public following upwards of $430m in venture funding.

The medical data software producer has filed to float in Hong Kong after raising nearly $340m from investors including Tencent and Sunshine Insurance.

The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.

The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.

Alphabet-backed short-term accommodation portal Airbnb has confidentially filed to go public, having raised money at a $26bn valuation in April.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

The immuno-oncology company – co-founded by Juno Therapeutics, a spinout of several institutions – is reportedly seeking $250m to $300m in a Hong Kong offering.